Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
about
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers.Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review.Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 triaClinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.Prognostic gene expression assays in breast cancer: are two better than one?Clinical relevance of the 21-gene Recurrence Score assay in treatment decisions for patients with node-positive breast cancer in the genomic eraAdherence to guidelines in requesting Oncotype DX in a publicly funded health care system
P2860
Q38374747-2A27B063-BA55-4F2C-BF1E-3FD36F6468ECQ38747402-6A8F9DC9-870E-495E-B02D-F114F284E626Q39489143-347E662B-A148-4554-945B-648C58062C0BQ41476022-ED603EAC-93F3-480B-9E00-7F5CFEA5587BQ41481374-66CF6E37-8AE9-414D-B844-F43014C3D663Q42670058-F721AA7E-B967-464B-8AD2-028007C040B0Q46082799-476B0449-7540-4585-AF73-C723E4AD093FQ47604446-FAB1A585-77B8-4F21-95C6-38B4A7766413Q48110842-BE2831D5-BA41-421F-812F-C09EAF9D6F23Q48163403-9CE0E938-FB39-4999-8668-F3C8EF669555Q48248768-8A9D3930-5269-487E-8359-019FA6DC1436Q50869231-4516BF9F-E668-45B9-988E-C0D2010D6776Q51136930-D113C084-D998-4A68-A72C-BF809E4DCC18Q55096327-E7BB768B-992D-41F2-90E0-B6B7CFB9E6F0Q55334991-D68B3199-E89E-4942-8DF3-E10797CF0B52Q55346547-D2EA46E8-FD43-4C95-9F4A-C0E878FBFDDBQ57107755-2C7AF199-06B9-4485-9719-5FC4EA608E0FQ58783192-B4ED0526-44F3-4FEB-9C8B-59BBF9C34BC6
P2860
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Breast-cancer-specific mortali ...... a SEER population-based study.
@ast
Breast-cancer-specific mortali ...... a SEER population-based study.
@en
type
label
Breast-cancer-specific mortali ...... a SEER population-based study.
@ast
Breast-cancer-specific mortali ...... a SEER population-based study.
@en
prefLabel
Breast-cancer-specific mortali ...... a SEER population-based study.
@ast
Breast-cancer-specific mortali ...... a SEER population-based study.
@en
P2093
P2860
P1433
P1476
Breast-cancer-specific mortali ...... a SEER population-based study.
@en
P2093
Ann G Schwartz
Antoinette Stroup
Brenda Y Hernandez
Carol Sweeney
Charles F Lynch
Charles Wiggins
Dave P Miller
Frederick L Baehner
Kathleen Cronin
Kevin C Ward
P2860
P2888
P356
10.1038/NPJBCANCER.2016.17
P577
2016-06-08T00:00:00Z
P6179
1003547846